trending Market Intelligence /marketintelligence/en/news-insights/trending/zlx0zx20qsrktg1m-q5dqg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UK regulator flags violations at Indoco Remedies' manufacturing plant

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

UK regulator flags violations at Indoco Remedies' manufacturing plant

Indoco Remedies Ltd. said the U.K.'s Medicines and Healthcare Products Regulatory Agency recorded seven violations at its manufacturing plant in Goa, India.

The agency identified three critical and four major violations at the facility after a three-day inspection that ended March 16, the company said.

The company plans to resolve the issue and respond to the U.K. regulator at the earliest.

Mumbai, India-based Indoco manufactures and markets formulations and active pharmaceutical ingredients in India, U.S., the European Union, South Africa, Australia and New Zealand.